SUPPLEMENTARY FIGURE. Sensitivity analysis of weekly monkeypox incidence,* by first dose vaccination status† among the estimated population of gay or bisexual men who have sex with men aged 18–49 years§ — 32 U.S. jurisdictions,¶,** July 31–September 3, 2022



Abbreviation: IRR = incidence rate ratio

* Cases per 100,000 population. Rate in vaccinated persons = number of probable or confirmed cases reported to CDC with date of illness onset, specimen collection, lab test completion, admission, diagnosis, discharge, case investigation start date, or date first electronically submitted or reported to the county, state, or public health department (earliest available date) ≥14 days after receiving the first dose of JYNNEOS vaccine among total vaccinated population as of 2 weeks prior. Rate in unvaccinated persons = number of probable or confirmed cases reported to CDC without evidence of vaccination among total unvaccinated population.

† Vaccinated = receipt of ≥1 JYNNEOS vaccine dose ≥14 days earlier.

§ Sensitivity analysis that expands the estimated number of persons eligible for vaccination from the estimated population per jurisdiction of gay or bisexual men who have sex with men (MSM) with HIV or eligible for HIV preexposure prophylaxis to the total estimated population per jurisdiction of MSM. Average IRR in sensitivity analysis was 5.5 (95% CI = 1.9–16.3). Average IRR in main analysis that estimates the population eligible for vaccination as the estimated population per jurisdiction of gay or bisexual men who have sex with men (GB-MSM) with HIV or are eligible for HIV pre-exposure prophylaxis was 14.3 (95% CI = 5.0-41.0)

¶ Alaska, California, Colorado, Georgia, Hawaii, Idaho, Illinois, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Missouri, Montana, Nevada, New Hampshire, New Mexico, North Dakota, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Utah, Virginia, West Virginia, and Wisconsin.

** Jurisdictions were included if age and sex assigned at birth or gender identity was available for ≥70% of cases reported, vaccination status was available for ≥50% of cases in males (defined by either sex assigned at birth or gender identity) aged 18–49 years or the jurisdiction confirmed cases are linked to immunization registry entries, and de-identified vaccination administration data were submitted to CDC.